Redhill Biopharma Ltd ADR buy melinda
Start price
21.10.17
/
50%
€8.41
Target price
10.11.17
€9.92
Performance (%)
-41.52%
End price
10.11.17
€4.92
Summary
This prediction ended on 10.11.17 with a price of €4.92. Massive losses of -41.52% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Redhill Biopharma Ltd ADR | - | - | - | - |
| iShares Core DAX® | -0.559% | 0.738% | 14.807% | 57.558% |
| iShares Nasdaq 100 | -0.566% | -0.324% | 3.991% | 86.023% |
| iShares Nikkei 225® | 1.073% | 5.624% | 19.546% | 49.340% |
| iShares S&P 500 | 0.868% | 0.030% | 1.475% | 58.072% |
Comments by melinda for this prediction
In the thread Redhill Biopharma Ltd ADR diskutieren
Biopharma
RedHill Biopharma Ltd.
RedHill Biopharma erhält Bezeichnung von der FDA Orphan - Drug für MESUPRON gegen Bauchspeicheldrüsenkrebs
(Vom Mitglied beendet)
Stopped prediction by melinda for Redhill Biopharma Ltd ADR
Redhill Biopharma Ltd ADR
Start price
Target price
Perf. (%)
€8.60
13.10.20
13.10.20
€10.00
04.11.21
04.11.21
-43.26%
05.11.21
05.11.21
Redhill Biopharma Ltd ADR
Start price
Target price
Perf. (%)
€8.68
04.05.17
04.05.17
€9.47
17.05.17
17.05.17
3.22%
17.05.17
17.05.17
Redhill Biopharma Ltd ADR
Start price
Target price
Perf. (%)
€9.97
31.05.16
31.05.16
€11.28
19.07.16
19.07.16
6.43%
19.07.16
19.07.16


